Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

Early-Stage Breast Carcinoma Clinical Trial

— PREDIX LumB  

Official title:

PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors With High Proliferation or Low Proliferation With Metastatic Nodes. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02603679
• Other study ID #: PREDIX LumB
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 2015
• Est. completion date: December 31, 2031

Study information

• Verified date: July 2021
• Source: Karolinska University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this neoadjuvant trial is to evaluate efficacy and toxicity of chemotherapy using weekly paclitaxel (arm A) versus the combination of the cdk 4/6 inhibitor palbociclib and standard endocrine treatment (arm B). After 12 weeks treatment is switched crossover. During the 24-weekly treatment period, clinical and radiological evaluations are performed repeatedly. Switch between the treatment arms A and B is allowed in case of lack of response or due to toxicity. A translational subprotocol is a mandatory part of the study protocol, except for use of PET-CT evaluations. Postoperatively, patients receive three 3-weekly courses of chemotherapy with a combination of epirubicin and cyclophosphamide.

Description:

Patients are randomized to either weekly treatment with paclitaxel (arm A) or endocrine treatment in combination with palbociclib (arm B) for 12 weeks. Choice of endocrine treatment is for pre- and perimenopausal women and all men tamoxifen 20 mg daily, alternatively for women in this age cohort, an LHRH analogue in combination with an aromatase inhibitor, for all postmenopausal women treatment with an aromatase inhibitor. The aromatase inhibitors to be used according to local practice are anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 2.5 mg daily. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women). Postmenopausal women receive an aromatase inhibitor.

After 12 weeks, patients without signs of disease progression (PD) are switched to either endocrine treatment in combination with palbociclib (arm A) or weekly treatment with paclitaxel (arm B) for 12 weeks. Postoperatively, patients receive three 3-weekly courses of chemotherapy with a combination of epirubicin and cyclophosphamide.

Before start, after 6, 12, 18 and 24 weeks of treatment, radiological assessments of tumor size are performed using mammography and ultrasound alt. MRI breast; PET-CT, confined to the breast and regional lymph nodes, before start, after 12 and 24 weeks, blood tests before start, after 1 week, 12, 18 and 24 weeks. Physical examinations are performed before start and then four-weekly after weeks 4, 8, 12, 16, 20 and 24 weeks of treatment.

In case of disease progression during ongoing study treatment, individualized management in the patient's best interest must be considered, in which case surgery is the primary option.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 181
• Est. completion date: December 31, 2031
• Est. primary completion date: July 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent

2. Female or male patients with breast cancer confirmed by histology

3. Tumor and blood samples available. Luminal B type confirmed by immunohistochemistry or, preferably, genomic profiling using Next-Generation Sequencingwith ER =120% and Ki67 =20% and not HER2 amplified, or, if aged 40 or younger and/or verified lymph node metastases, luminal A type, defined as ER and PR positive =20% and the proliferation marker Ki 67 <20% and not HER2 amplified. Any luminal B, Luminal A with verified lymph node metastases and/or aged 40 or younger

4. Age 18 years or older. Elderly patients in condition adequate for planned therapy

5. Primary breast cancer >20mm in diameter and/or verified regional lymph node metastases

6. Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled medical or psychiatric disorders

7. LVEF >55%

8. ECOG performance status 0-1

9. Primary breast cancer as defined in p. 5 plus at most 2 morphologically characterized well-defined distant metastases accessible for stereotactic radiotherapy, provided that this treatment is available

Exclusion Criteria:

1. Distant metastases, including node metastases in the contralateral thoracic region or in the mediastinum

2. Other malignancy diagnosed within the last five years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix

3. Patients in child-bearing age without adequate contraception

4. Pregnancy or lactation

5. Uncontrolled hypertension, heart, liver, kidney related or other medical or psychiatric disorders

Related Conditions & MeSH terms

• Breast Neoplasms
• Early-Stage Breast Carcinoma
• Estrogen Receptor Positive Tumor

Intervention

Drug:
• Paclitaxel
Any brand of paclitaxel may be used, excluding nab-paclitaxel
• Tamoxifen + Palbociclib
Any brand of tamoxifen may be used
• Aromatase Inhibitor + Palbociclib
Any brand of letrozole, anastrozole or exemestane may be used
• Goserelin + Aromatase Inhibitor + Palbociclib
Any brand of letrozole, anastrozole or exemestane may be used

Locations

Country	Name	City	State
Sweden	Capio S:t Göran Hospital	Stockholm
Sweden	Karolinska University Hospital	Stockholm
Sweden	Södersjukhuset	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Thomas Hatschek

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiological Objective Response Rate after Completion of the First 12-week Period of Primary Medical Treatment	Radiological response by use of mammography and ultrasound, alternatively MRI of the breast, if mammography/ultrasound does not allow for objective measurements of the primary tumor. Clinical measurements using calliper, if the tumor is palpable and tumor size cannot be estimated by radiological methods	Start of treatment until 12 weeks of treatment
Secondary	Pathological Objective Response Rate	Presence/abscense of residual tumor in mm, fibrosis and other signs of response by histology	From the date of surgery up to 4 weeks after surgery
Secondary	Sequencing of Chemotherapy versus Endocrine Treatment plus Palbociclib in relation to Radiological Objective Response Rate after Completion of the 24-week Period of Primary Medical Treatment	Radiological response by use of mammography and ultrasound, alternatively MRI of the breast, if mammography/ultrasound does not allow for objective measurements of the primary tumor. Clinical measurements using calliper, if the tumor is palpable and tumor size cannot be estimated by radiological methods	From start of treatment until termination of the preoperative treatment after 24 weeks
Secondary	Disease-Free Survival	Disease-free survival includes all events related to breast cancer, and death from any cause during the follow-up period	From date of surgery until 10 years past surgery
Secondary	Breast Cancer-Specific Survival	Breast cancer-specific survival includes all events related to breast cancer and death caused by breast cancer during the follow-up period	From date of surgery until 10 years past surgery
Secondary	Overall Survival	Overall survival relates to death from any cause during the follow-up period	From date of surgery until 10 years past surgery
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Safety will be assessed using NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE) for reporting laboratory and non-laboratory toxicities	From start of treatment until 28 days after termination of 24 weeks of treatment. Delayed toxicity is reported until 60 months follow-up
Secondary	Health-Related Quality of Life		From start of study treatment until termination after 24 weeks, and then annually during 5 years of postoperative follow-up period
Secondary	Frequency of Breast-Conserving Surgery	Refers to the rate of patients who are operated with breast-conserving surgery compared with mastectomy	At surgery after neoadjuvant therapy
Secondary	Characteristics of the Genome of Previously Untreated Tumors Before and After Exposition to Treatment	New Generation Sequencing (NGS) is performed on biopsies from the tumors with the aim to classify the tumors according to PAM50. Repeated analyses of tumor tissue during the treatment process will be performed to identify heterogeneity and mutations which might be responsible for resistance to study treatment. Blood samples are collected to identify tumor DNA sequences which might predict recurrence during the follow-up period. Tissue and blood samples are also analyzed in case of recurrence. The results are descriptive and expressed as clustering. Units of measure are lacking	Before start and during treatment, at surgery, and then annually during the 60 months of postoperative follow-up period
Secondary	Changes of the Proteome of Previously Untreated Tumors Before and After Exposition to Treatment	Proteome analyses with the intention to identify tumor-specific pathways are performed on repeated biopsies from the tumors. The results are descriptive, defined units of measure are lacking	Before start, during treatment and at surgery
Secondary	Quantification of Hormone Receptors Before and After Treatment	Immunohistochemistry on core biopsies before start, after 10 weeks of treatment, and tumor samples from the surgical specimen. Presence of estrogen receptor (ER) and progesterone receptor (PR), described as percentage in relation to the total count of tumor cells	Before start, during treatment and at surgery
Secondary	Quantification of Proliferation Before and After Treatment	Immunohistochemistry on core biopsies before start, after 10 weeks of treatment, and tumor samples from the surgical specimen. Presence of cells indicating proliferation by use of Ki67, described as percentage in relation to the total count of tumor cells	Before start, during treatment and at surgery